| Peter Merrill Jensen, DO | |
|
1208 Hilltop Dr, Suite 200, Rock Springs, WY 82901-5857 | |
| (307) 382-4114 | |
| (307) 382-4131 |
| Full Name | Peter Merrill Jensen |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Experience | 32 Years |
| Location | 1208 Hilltop Dr, Rock Springs, Wyoming |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1306826938 | NPI | - | NPPES |
| 110943000 | Medicaid | WY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | 5692A (Wyoming) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Memorial Hospital Sweetwater County | Rock springs, WY | Hospital |
| Entity Name | Peak Vision Eye Surgery Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1164618369 PECOS PAC ID: 3678639440 Enrollment ID: O20090303000147 |
News Archive
Roche NimbleGen announces that Southern California (Aliso Viejo) based genomic services provider Ambry Genetics has officially become a Certified Service Provider (CSP) for the NimbleGen SeqCap EZ Exome workflow. They will provide target-enrichment services using NimbleGen SeqCap EZ Human Exome coupled with next-generation sequencing services for genetic research.
According to a recent study, led by Virginia Kaklamani, MD, an oncologist at Northwestern Memorial Hospital and assistant professor of medicine, Northwestern University Feinberg School of Medicine, variations of the adiponectin gene, which regulates a number of metabolic processes, may increase a woman's risk of developing breast cancer.
Almost all of our genes may be influenced by the food we eat, suggests new research published today in the journal Nature Microbiology. The study, carried out in yeast - which can be used to model some of the body's fundamental processes - shows that while the activity of our genes influences our metabolism, the opposite is also true and the nutrients available to cells influence our genes.
Momenta Pharmaceuticals, Inc., a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that the U.S. Food and Drug Administration has granted marketing approval of the Abbreviated New Drug Application for enoxaparin sodium for injection filed by Sandoz. Developed under a collaboration agreement between Momenta and Sandoz, this product has been designated therapeutically equivalent to the reference-listed drug, Lovenox, which is marketed by Sanofi-Aventis.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Peter Merrill Jensen, DO 1208 Hilltop Dr, Suite 200, Rock Springs, WY 82901-5857 Ph: (307) 382-4114 | Peter Merrill Jensen, DO 1208 Hilltop Dr, Suite 200, Rock Springs, WY 82901-5857 Ph: (307) 382-4114 |
News Archive
Roche NimbleGen announces that Southern California (Aliso Viejo) based genomic services provider Ambry Genetics has officially become a Certified Service Provider (CSP) for the NimbleGen SeqCap EZ Exome workflow. They will provide target-enrichment services using NimbleGen SeqCap EZ Human Exome coupled with next-generation sequencing services for genetic research.
According to a recent study, led by Virginia Kaklamani, MD, an oncologist at Northwestern Memorial Hospital and assistant professor of medicine, Northwestern University Feinberg School of Medicine, variations of the adiponectin gene, which regulates a number of metabolic processes, may increase a woman's risk of developing breast cancer.
Almost all of our genes may be influenced by the food we eat, suggests new research published today in the journal Nature Microbiology. The study, carried out in yeast - which can be used to model some of the body's fundamental processes - shows that while the activity of our genes influences our metabolism, the opposite is also true and the nutrients available to cells influence our genes.
Momenta Pharmaceuticals, Inc., a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that the U.S. Food and Drug Administration has granted marketing approval of the Abbreviated New Drug Application for enoxaparin sodium for injection filed by Sandoz. Developed under a collaboration agreement between Momenta and Sandoz, this product has been designated therapeutically equivalent to the reference-listed drug, Lovenox, which is marketed by Sanofi-Aventis.
› Verified 1 days ago